Arkolith/Insider Trading/GANX/Form 4

Ballantyne Charles Evan

Chief Financial OfficerGain Therapeutics, Inc. (GANX) · full profile →Form 4 · filed Apr 12, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 10, 2023Grant(A)50K—$050K
Apr 10, 2023Grant(A)100K—$0100K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-024125) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML